Successful suppression of the EGFR/MAPK/MMP-2 pathway following the addition of gefitinib in ESCC cells with stably overexpressed RNF128 was confirmed by the diminished expression of p-EGFR, p-MEK, p-ERK, and MMP-2 proteins (Figure 4A). Here, EGFR is linked to esophageal squamous cell carcinoma.